ASCO 2022 Conference Coverage
Playback speed
10 seconds
Health-Related Quality of Life in R/R MM Treated With Teclistamab, a B-Cell Maturation Antigen x CD3-Bispecific Antibody: PROs in MajesTEC-1
773 views
June 20, 2022
This video was recorded prior to the FDA approval of teclistamab-cqyv (TECVAYLI) for adult patients ...
read more ↘ with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy.
↖ read less
read more ↘ with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy.
↖ read less
Comments 0
Login to view comments.
Click here to Login
Myeloma